Single-Voxel MR Spectroscopy of Gliomas with s-LASER at 7T

Background and Purpose: Magnetic resonance spectroscopy (MRS)—a method of analysing metabolites in vivo—has been utilized in several studies of brain glioma biomarkers at lower field strengths. At ultra-high field strengths, MRS provides an improved signal-to-noise-ratio and spectral resolution, but 7T studies on patients with gliomas are sparse. The purpose of this exploratory study was to evaluate the potential clinical implication of the use of single-voxel MRS at 7T to assess metabolic information on lesions in a pilot cohort of patients with grade II and III gliomas. Methods: We scanned seven patients and seven healthy controls using the semi-localization by adiabatic-selective refocusing sequence on a Philips Achieva 7T system with a standard dual-transmit head coil. The metabolic ratios were calculated relative to water and total creatine. Additionally, 2-hydroxyglutarate (2-HG) MRS was carried out in four of the patients, and the 2-HG concentration was calculated relative to water. Results: When comparing the tumour data to control regions in both patients and healthy controls, we found that the choline/creatine and myo-inositol/creatine ratios were significantly increased and that the N-acetylaspartate/creatine and the neurotransmitter glutamate/creatine ratios were significantly decreased. The N-acetylaspartate/water and glutamate/water ratios were also significantly decreased. The lactate/water and lactate/creatine ratios showed increases, although not significant. The GABA/water ratio was significantly decreased, but the GABA/creatine ratio was not. MRS spectra showed the presence of 2-HG in three of the four patients studied. Three of the patients, including the MRS 2-HG-negative patient, were operated on, and all of them had the IDH mutation. Conclusion: Our findings were consistent with the existing literature on 3T and 7T MRS.

[1]  K. Young,et al.  Vespa: Integrated applications for RF pulse design, spectral simulation and MRS data analysis , 2023, Magnetic resonance in medicine.

[2]  D. Klomp,et al.  Comparison of 2-Hydroxyglutarate Detection With sLASER and MEGA-sLASER at 7T , 2021, Frontiers in Neurology.

[3]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[4]  Wolfgang Bogner,et al.  Contribution of macromolecules to brain 1H MR spectra: Experts' consensus recommendations , 2020, NMR in biomedicine.

[5]  Anke Henning,et al.  B0 shimming for in vivo magnetic resonance spectroscopy: Experts' consensus recommendations , 2020, NMR in biomedicine.

[6]  S. Venneti,et al.  Glutamine Metabolism in Brain Tumors , 2019, Cancers.

[7]  D. Norris,et al.  A comparison of sLASER and MEGA-sLASER using simultaneous interleaved acquisition for measuring GABA in the human brain at 7T , 2019, PloS one.

[8]  Esben Thade Petersen,et al.  Improvement in diagnostic quality of structural and angiographic MRI of the brain using motion correction with interleaved, volumetric navigators , 2019, PloS one.

[9]  Wolfgang Bogner,et al.  High-resolution metabolic mapping of gliomas via patch-based super-resolution magnetic resonance spectroscopic imaging at 7T , 2019, NeuroImage.

[10]  P. Kwan,et al.  Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging , 2019, NeuroImage: Clinical.

[11]  Peter Jezzard,et al.  A comparison of 2‐hydroxyglutarate detection at 3 and 7 T with long‐TE semi‐LASER , 2018, NMR in biomedicine.

[12]  Yan Li,et al.  Comparison between Short and Long Echo Time Magnetic Resonance Spectroscopic Imaging at 3T and 7T for Evaluating Brain Metabolites in Patients with Glioma. , 2017, ACS chemical neuroscience.

[13]  Wolfgang Bogner,et al.  Key clinical benefits of neuroimaging at 7 T , 2016, NeuroImage.

[14]  H. Land,et al.  Addiction to Coupling of the Warburg Effect with Glutamine Catabolism in Cancer Cells , 2016, Cell reports.

[15]  Hui Zhang,et al.  The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: A systematic review and meta-analysis , 2016, European Radiology.

[16]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[17]  Andrei I Holodny,et al.  Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. , 2016, Neuro-oncology.

[18]  J. Lupo,et al.  Magnetic Resonance (MR) Metabolic Imaging in Glioma , 2015, Brain pathology.

[19]  Eugene Ozhinsky,et al.  Short‐echo three‐dimensional H‐1 MR spectroscopic imaging of patients with glioma at 7 tesla for characterization of differences in metabolite levels , 2015, Journal of magnetic resonance imaging : JMRI.

[20]  K. Aldape,et al.  IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas , 2015, Acta Neuropathologica.

[21]  M. Bruno,et al.  Quantitative rates of brain glucose metabolism distinguish minimally conscious from vegetative state patients , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  H. Duffau,et al.  New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach. , 2014, Neuro-oncology.

[23]  N. Danbolt,et al.  Glutamate as a neurotransmitter in the healthy brain , 2014, Journal of Neural Transmission.

[24]  Jens Frahm,et al.  Clinical proton MR spectroscopy in central nervous system disorders. , 2013, Radiology.

[25]  R. Caivano,et al.  3 Tesla magnetic resonance spectroscopy: cerebral gliomas vs. metastatic brain tumors. Our experience and review of the literature , 2013, The International journal of neuroscience.

[26]  A. Škoch,et al.  Potential of MR spectroscopy for assessment of glioma grading , 2013, Clinical Neurology and Neurosurgery.

[27]  Peter R Luijten,et al.  Efficient spectral editing at 7 T: GABA detection with MEGA‐sLASER , 2012, Magnetic resonance in medicine.

[28]  Ovidiu C. Andronesi,et al.  Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.

[29]  Z. Bhujwalla,et al.  Choline metabolism in malignant transformation , 2011, Nature Reviews Cancer.

[30]  P R Luijten,et al.  7‐T 1H MRS with adiabatic refocusing at short TE using radiofrequency focusing with a dual‐channel volume transmit coil , 2011, NMR in biomedicine.

[31]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[32]  Andrei G. Vlassenko,et al.  Regional aerobic glycolysis in the human brain , 2010, Proceedings of the National Academy of Sciences.

[33]  P. Barker,et al.  Imaging of brain tumors: MR spectroscopy and metabolic imaging. , 2010, Neuroimaging clinics of North America.

[34]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[35]  Carles Arús,et al.  Automated quality control protocol for MR spectra of brain tumors , 2008, Magnetic resonance in medicine.

[36]  Margarida Julià-Sapé,et al.  MRS quality assessment in a multicentre study on MRS‐based classification of brain tumours , 2008, NMR in biomedicine.

[37]  D. Dormont,et al.  Spectroscopie par résonance magnétique cérébrale , 2007 .

[38]  R. Gruetter,et al.  Methodology of1H NMR spectroscopy of the human brain at very high magnetic fields , 2005, Applied magnetic resonance.

[39]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[40]  Damien Galanaud,et al.  Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. , 2003, Journal of neurosurgery.

[41]  R Gruetter,et al.  Automatic, localized in Vivo adjustment of all first‐and second‐order shim coils , 1993, Magnetic resonance in medicine.

[42]  Peter Jezzard,et al.  Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations. , 2016, Cancer research.

[43]  P. Barker,et al.  MR spectroscopy and spectroscopic imaging of the brain. , 2011, Methods in molecular biology.

[44]  Kiyohiro Houkin,et al.  In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. , 2004, Magnetic resonance imaging.

[45]  D. Leibfritz,et al.  Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. , 1993, Developmental neuroscience.

[46]  Jeanine Weekes Schroer,et al.  The Finite String Newsletter Abstracts of Current Literature Glisp User's Manual , 2022 .